Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.
Ritchie AJ. et al, (2025), Vaccine, 47
A screen for Plasmodium falciparum sporozoite surface protein binding to human hepatocyte surface receptors identifies novel host-pathogen interactions.
Segireddy RR. et al, (2024), Malaria journal, 23
Accelerated and intensified manufacturing of an adenovirus-vectored vaccine to enable rapid outbreak response.
Joe CCD. et al, (2023), Biotechnology and bioengineering
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
Measurement of Adenovirus-Based Vector Heterogeneity.
Hickey JM. et al, (2023), Journal of pharmaceutical sciences, 112, 974 - 984
Rapid-response manufacturing of adenovirus-vectored vaccines
Joe CCD. et al, (2023), Nature Biotechnology
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
Jenkin D. et al, (2022), The Lancet Microbe, 3, e663 - e671
Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies.
Ng WM. et al, (2022), Cell host & microbe, 30, 1219 - 1230.e7
STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.
Padron-Regalado E. et al, (2022), Scientific reports, 12
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T H 1 response with a diverse TCR repertoire
Swanson PA. et al, (2021), Science Translational Medicine, 13
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040
Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Dulal P. et al, (2021), Scientific reports, 11
Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Dulal P. et al, (2021), Scientific reports, 11
Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations.
Berg A. et al, (2021), Vaccines, 9
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
Frater J. et al, (2021), The Lancet HIV, 8, e474 - e485